|
 Only 785,500 J&J doses will be allocated, compared to 4.95 million
doses this week. The U.S. Department of Health and Human Services (HHS)
and J&J did not immediately respond to requests, made outside
regular hours, for comment on the drop in numbers.
A New York Times report last week said that workers at an Emergent
BioSolutions facility in Baltimore, which produced both AstraZeneca
Plc and J&J doses, mixed up ingredients of the two vaccines, ruining
15 million J&J doses.
However, the Baltimore facility has not yet been authorized by the
U.S. Food and Drug Administration, and a federal health official
told Reuters last week that none of the vaccine doses from the plant
have been used in vaccination efforts so far.
J&J has reiterated that it expected to deliver 100 million doses to
the government by the end of May.
[to top of second column] |
 According to the CDC data,
California is the main recipient of the J&J
vaccine, followed by Texas and Florida. The
vaccine allocation for California is down by
about 88%, with the state set to receive only a
maximum of 67,600 doses next week.
A California health official told Reuters that the number will be
down further in the week starting April 18, with only 22,400 doses
of the J&J vaccine allocated to the state.
U.S. President Joe Biden on Tuesday moved up the COVID-19 vaccine
eligibility target for all American adults to April 19.
(Reporting by Shubham Kalia and Aakriti Bhalla in Bengaluru; Editing
by Simon Cameron-Moore)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
